Answers are grounded in this paper and cite their sources.
Our results suggest an important contribution of TROP2 expression to the primary resistance to PD-L1 blockade in NSCLC. TROP2-biomarker-based strategy may be relevant in selecting patients with NSCLC who are more likely to benefit from a combination of immunotherapy and an anti-TROP2 agent.
No takes yet. Share an insight, caveat, or question.
Bessede et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: